Novavax (NVAX) Depreciation & Amortization (CF) (2010 - 2026)

Novavax's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 63.29% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $22.3 million, a 50.02% decrease from a year earlier, with the FY2025 full-year figure at $27.6 million, down 43.06% from the prior year.
• Depreciation & Amortization (CF) fell to $3.1 million in Q1 2026 per NVAX's latest filing, from $5.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $12.7 million in Q3 2024 and bottomed at $3.1 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $8.3 million (2022), against an average of $8.8 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 191.97% in 2022 and slumped 63.29% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $7.2 million in 2022, then soared by 49.46% to $10.8 million in 2023, then advanced by 15.96% to $12.5 million in 2024, then sank by 59.06% to $5.1 million in 2025, then slumped by 40.25% to $3.1 million in 2026.
• Per Business Quant, the three latest NVAX Depreciation & Amortization (CF) figures stand at $3.1 million (Q1 2026), $5.1 million (Q4 2025), and $6.6 million (Q3 2025).